← Eichor
Study identifier: NCT07359014 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma

Condition: Relapse Multiple Myeloma  ·  Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

PhaseNA
Planned participants25
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This study aims to investigate the efficacy and safety of CD19/BCMA CAR-T cells in treating relapsed/refractory multiple myeloma.

This description comes directly from the study's public registry record.

Talk to the study team

Xuzhao Zhang  ·  +86-571-89713679  ·  zxzzju@zju.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Xuzhao ZhangHangzhou, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07359014